
Aspriant Pharmaceuticals Private Limited
About Aspriant Pharmaceuticals Private Limited
Data last updated:
Aspriant Pharmaceuticals Private Limited is a private limited company based in Washim, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 07 January 2015 and has been in existence for over 11 years.
The company is registered with the Registrar of Companies (ROC), Nagpur, under CIN U24233MH2015PTC260715. Its GSTIN is 27AANCA1719Q1Z4 (Maharashtra).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Akash Rameshwar Katekar and Dipali Prakash Gote.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Nirmal Laxmi Nagar Old I U D P Near Mahalaxmi Temple, Washim, Maharashtra, India – 444505.
As per the financials filed for FY 2024, the company reported a revenue of ₹31.19 Lakh, a growth of 100% compared to the previous year. For the same year it recorded a net profit of ₹41,410 (net margin 1.3%) and EBITDA of ₹3.54 Lakh (EBITDA margin 11.4%). Revenue has grown at a compounded annual rate (CAGR) of 75% over three years.
As per MCA filings, the company has open charges of ₹30 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Aspriant Pharmaceuticals Private Limited's registered office is in Washim, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressNirmal Laxmi Nagar Old I U D P Near Mahalaxmi Temple, Washim, Maharashtra, India – 444505
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Aspriant Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Aspriant Pharmaceuticals is trade. In detail, this covers retail trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading |
To see the full business activity and turnover split of Aspriant Pharmaceuticals Private Limited, buy the company report.
Financials of Aspriant Pharmaceuticals Private Limited
FY 2024 filings availableAspriant Pharmaceuticals Private Limited reported revenue of ₹31.19 Lakh (up 100% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 75% over three years, including 100% growth in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3.54 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹41,410 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.4% | ||||
| Net Profit Margin | 1.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Aspriant Pharmaceuticals Private Limited, buy the company report.
Board of directors of Aspriant Pharmaceuticals Private Limited
Aspriant Pharmaceuticals has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Akash Rameshwar Katekar | Director | 23 Oct 2020 | 6 Years 0 Months | Current |
| Dipali Prakash Gote | Director | 23 Oct 2020 | 6 Years 0 Months | Current |
Peer comparison
Aspriant Pharmaceuticals Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (retail trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Metan Pharmaceuticals Private Limited | ₹31.3 Lakh (FY 2025) | 49.0% | Guntur, Andhra Pradesh, India | |||
| Exide Healthcare Pharmaceuticals Private Limited | ₹31.26 Lakh (FY 2025) | -25.0% | New Delhi, Delhi, India | |||
| Shri Gangadas Distributors Private Limited | ₹31.24 Lakh (FY 2023) | 218.0% | Jaipur, Rajasthan, India | |||
| Aspriant Pharmaceuticals Private Limitedthis company | ₹31.19 Lakh (FY 2024) | ₹41,410 | 1.3% | 100.0% | Washim, Maharashtra, India |
To see the full peer comparison of Aspriant Pharmaceuticals Private Limited, buy the company report.
Auditor
Aspriant Pharmaceuticals Private Limited is audited by BHOYAR AND CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BHOYAR AND CO. | FY 2023 | 132522W |
Shareholding
The shareholding of Aspriant Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Aspriant Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 18 May 2023 | 100733100 | Others | ₹30 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Aspriant Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Aspriant Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Aspriant Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AANCA1719Q1Z4 | Maharashtra | Active | 18 Nov 2020 |
To see the full GST registrations and return filing status of Aspriant Pharmaceuticals Private Limited, buy the company report.
Recent activity
Aspriant Pharmaceuticals Private Limited has 6 board changes on record since 2015: 4 appointments and 2 cessations. The latest: Laxman Vikram More ceased to be Director on 04 Nov 2020.
Frequently asked questions
Aspriant Pharmaceuticals is an active private limited company based in Washim, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 07 January 2015 (11+ years old) and is registered under CIN U24233MH2015PTC260715.
Aspriant Pharmaceuticals has 2 current directors:
- Akash Rameshwar Katekar - Director
- Dipali Prakash Gote - Director
The latest financial statements of Aspriant Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Aspriant Pharmaceuticals is 27AANCA1719Q1Z4, registered in Maharashtra.
The CIN (Corporate Identification Number) of Aspriant Pharmaceuticals is U24233MH2015PTC260715. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Aspriant Pharmaceuticals was incorporated on 07 January 2015, making it 11+ years old. It is registered with the Registrar of Companies, Nagpur.
The peers of Aspriant Pharmaceuticals by revenue are Metan Pharmaceuticals Private Limited, Exide Healthcare Pharmaceuticals Private Limited, Shri Gangadas Distributors Private Limited, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (retail trading).
Laxman Vikram More ceased to be Director on 04 Nov 2020. Prashant Janardhan Divthane ceased to be Director on 04 Nov 2020. Akash Rameshwar Katekar was appointed as Director on 23 Oct 2020. Aspriant Pharmaceuticals has 6 board changes on record in total.
The registered office of Aspriant Pharmaceuticals is at Nirmal Laxmi Nagar Old I U D P Near Mahalaxmi Temple, Washim, Maharashtra, India – 444505.
Aspriant Pharmaceuticals operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
Aspriant Pharmaceuticals has open charges of ₹30 Lakh and no satisfied charges on record as per latest MCA filings.

